Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3317821 | 0.97 | CHRM2 (0.39) | CHRM2CHRM4CHRM1CHRM3POLB | |
| SCHEMBL592258 | 0.93 | OPRM1 (0.40) | CHRM2CHRM4CHRM1CHRM3OPRM1 | |
| Bromide SCHEMBL6628170 | 0.91 | OPRM1 (0.39) | CHRM2CHRM4CHRM1CHRM3OPRM1 | |
| SCHEMBL13398561 | 0.90 | OPRM1 (0.38) | CHRM2CHRM4CHRM1CHRM3OPRM1 | |
| SCHEMBL3220818 | 0.82 | OPRM1 (0.41) | KDM4EOPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL667330 | 0.81 | TSHR (0.40) | CHRM2CHRM4CHRM1CHRM3POLB | |
| SCHEMBL9050441 | 0.81 | CHRM2 (0.50) | CHRM2CHRM4CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL29435164 | 0.80 | OPRM1 (0.43) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Bromide SCHEMBL30309841 | 0.80 | OPRM1 (0.41) | POLBKDM4EOPRM1OPRD1OPRK1 | |
| SCHEMBL668021 | 0.79 | HCAR2 (0.40) | CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0287356-B1 | Bridgehead substituted azabicyclic derivatives | BEECHAM GROUP PLC (GB) | 1996-01-24 | — | — | EP | claimed |
| EP-0287356-A2 | Bridgehead substituted azabicyclic derivatives | BEECHAM GROUP PLC (GB) | 1988-10-19 | — | — | EP | claimed |
| US-8088760-B2 | Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2247600-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Lead Therapeutics, Inc. (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009099736-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| WO-2009029375-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062268-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| EP-0392803-B1 | Novel compounds | BEECHAM GROUP PLC (GB) | 2004-06-16 | — | — | EP | disclosed |
| EP-0366304-B1 | Heterocyclic derivatives, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1998-04-15 | — | — | EP | disclosed |
| US-RE35593-E | THERAPY FOR DERMENTIA | BEECHAM GROUP P.L.C. | 1997-08-19 | — | — | US | disclosed |
| US-4988706-A | Treatment of dementia in mammals, central nervous system disorders, cognition activators | BEECHAM GROUP P.L.C. (GB) | 1991-01-29 | — | — | US | disclosed |
| EP-0402056-A2 | Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them | Beecham Group p.l.c. (GB) | 1990-12-12 | — | — | EP | disclosed |
| US-4971975-A | TREATMENT OF DEMENTIA; AZABICYCLOOCTANE COMPOUNDS | BEECHAM GROUP PLC (GB) | 1990-11-20 | — | — | US | disclosed |
| EP-0392803-A1 | Novel compounds | Beecham Group p.l.c. (GB) | 1990-10-17 | — | — | EP | disclosed |
| EP-0366304-A2 | Heterocyclic derivatives, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1990-05-02 | — | — | EP | disclosed |
| EP-0363085-A2 | Novel compounds | BEECHAM GROUP PLC (GB) | 1990-04-11 | — | — | EP | disclosed |
| EP-0339834-A2 | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1989-11-02 | — | — | EP | disclosed |
| EP-0338723-A1 | Novel compounds | BEECHAM GROUP PLC (GB) | 1989-10-25 | — | — | EP | disclosed |
| EP-0287356-A2 | Bridgehead substituted azabicyclic derivatives | BEECHAM GROUP PLC (GB) | 1988-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | CHRM2 4479/4885CHRM4 4734/4885CHRM1 4421/4885 |
| US-20090062268-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP11, PARP2 | CHRM2 4390/4885CHRM4 4831/4885CHRM1 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.